ANTOFENOL

Their core work

ANTOFENOL is a French biotech SME developing natural bioactive compounds extracted from ants for agricultural and food protection applications. Their flagship product, ANTOFERINE, is produced through an eco-friendly, chemical solvent-free extraction process and acts as a natural fungicide for plant protection and post-harvest preservation of fruits and vegetables. They progressed from process development (SME Instrument Phase 1) to full commercial development (Phase 2, €2M+), indicating a product company on a market-entry trajectory rather than a pure research outfit. Their value proposition sits at the intersection of biocontrol, food safety, and reduced reliance on synthetic agrochemicals.

What they specialise in

How they've shifted over time

In their first project (2018), ANTOFENOL was focused entirely on the upstream challenge: how to extract bioactive compounds from ants without chemical solvents — a process and chemistry problem. By 2020, that process question was resolved and their focus had shifted downstream to the market application: using those compounds as a natural fungicide for post-harvest crop protection. This is a textbook SME Instrument progression — Phase 1 validates feasibility, Phase 2 funds commercialisation — and it signals a company that has moved from lab-scale innovation into product development and market entry.

ANTOFENOL is heading toward commercial launch of a natural fungicide product for the fruit and vegetable supply chain, making them a potential partner or supplier for agrifood companies seeking alternatives to synthetic post-harvest treatments.

How they like to work

ANTOFENOL has operated entirely as a solo entity — both projects have zero consortium partners, which is consistent with the SME Instrument design (grants for individual companies, not consortia). They led both projects as coordinator, but in practice this means they executed independently, not as part of a multi-partner team. Anyone looking to partner with them would be entering new territory for the company: they have no recorded history of consortium-based collaboration.

ANTOFENOL has no recorded consortium partners across their entire H2020 history — both projects were solo SME Instrument grants. They have no documented international research network within the EU framework.

What sets them apart

ANTOFENOL occupies a very specific niche: ant-derived natural compounds as commercial fungicides, produced without chemical solvents. This is an unusual biological source (most biocontrol products draw from bacteria, fungi, or plant extracts), which could represent a genuine IP moat if their extraction process is proprietary. For a consortium or business partner, they bring a ready-to-commercialise natural fungicide with EU-funded validation behind it — not a research concept, but a product in development.

Highlights from their portfolio

• ANTOFERINE
  The Phase 2 project (€2.06M, 2020–2022) is notable for its size relative to the company — a near-€2M solo grant is a strong EU validation signal that the technology passed rigorous feasibility review and has credible commercial potential.
• ANTOFERINE
  The Phase 1 project (2018, €50K) established the core IP: a chemical solvent-free extraction of bioactive compounds from ants, an unusual biological source not commonly seen in the EU biocontrol funding landscape.